Replies to post #247598 on Biotech Values

[stocksrising]

Dice Therapeutics Rallies As It Agrees To Be Bought By Lilly -- MarketWatch
Mentioned: DICE LLY
Dice Therapeutics Inc. (DICE) stock is up by 40% in premarket trades Tuesday after it agreed to be purchased by Eli Lilly & Co. (LLY) for $48 a share in a deal that values the immunology company at about $2.4 billion. The price values Dice at a 40% premium over the 30-day, volume-weighted average trading price of its stock as of June 16. "We're eager to see our pipeline, including our oral IL-17 inhibitors, DC-806 and DC-853, benefit from Lilly's resources and global reach and I'm excited by the prospect of watching these two talented teams in a united quest for scientific innovation," said Dice CEO Kevin Judice. Lilly stock is down 0.2% in premarket trades.

[dewophile]

I’ll leave comments about the lawsuit to the lawyers. My only observation is that companies that are more vulnerable to this legislation don’t seem to be trading at much if any discount to those that are more protected so either investors are confident pharma will effectively fight this or are not worried about a timeline beyond 4-5 years when this kicks into high gear (affecting more drugs including part B)